Northwest Biotherapeutics Inc. (NWBO) intrinsic value & 10-year financials
Northwest Biotherapeutics Inc. (NWBO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 9.2% a year to $1.4M, with an average return on invested capital of 948.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.16
- Market cap
- $228.0M
- Revenue (FY2025)
- $1.4M
- Revenue growth (10-yr CAGR)
- 9.2%
- ROIC (10-yr avg)
- 948.7%
- Free cash flow (FY2025)
- -$46.3M
NWBO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.4M | -$60.2M | -$0.04 | -$46.3M | -4347.9% | 418.0% |
| FY2024 | $1.4M | -$83.8M | -$0.00 | -$58.0M | -4812.4% | 254.8% |
| FY2023 | $1.9M | -$62.6M | -$0.00 | -$57.1M | -2873.1% | 84.2% |
| FY2022 | $1.7M | -$105.0M | -$0.00 | -$55.7M | -3991.7% | 63.8% |
| FY2021 | $1.0M | $179.1M | -$0.00 | -$44.3M | -5244.0% | 23.2% |
| FY2020 | $1.3M | -$529.8M | -$0.00 | -$38.7M | -6708.4% | 45.6% |
| FY2019 | $2.4M | -$20.3M | -$0.00 | -$32.0M | -1139.5% | 69.6% |
| FY2018 | $412.0K | -$35.8M | — | -$34.6M | -10068.2% | 93.6% |
| FY2017 | $336.0K | -$73.1M | — | — | -16273.2% | 295.6% |
| FY2016 | $623.0K | -$80.2M | — | — | -12723.3% | 8138.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NORTHWEST BIOTHERAPEUTICS INC is a consistent compounder, expanding top-line revenue at 9.2% annually over the past decade.
NORTHWEST BIOTHERAPEUTICS INC has earned high returns on invested capital, averaging 47.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Over the decade, NORTHWEST BIOTHERAPEUTICS INC shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NORTHWEST BIOTHERAPEUTICS INC is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.85 per share.